Sector News

Mylan says Teva’s stake buy violates U.S. anti-trust rules

June 2, 2015
Life sciences
(Reuters) – Mylan NV said Teva Pharmaceutical Industries Ltd , which has made an unsolicited offer for the company, violated U.S. anti-trust rules by acquiring a stake.
 
Teva disclosed a 1.35 percent stake in Mylan last week.
 
“We consider Teva’s stakebuilding as a further indication of its intention to meddle with our business, strategy and mission while remaining unclear as to its actual intentions,” Mylan said in a letter addressed to Teva’s chief executive, Erez Vigodman.(http://1.usa.gov/1Q0SxgC)
 
Mylan did not clarify which anti-trust rule Teva violated.
 
The two companies were not immediately available for comment.
 
Mylan said on Monday there was still no clarity whether Teva would make a formal offer, almost six weeks since Teva’s offer for about $40 billion.
 
(Reporting by Anjali Rao Koppala in Bengaluru; Editing by Maju Samuel)
 

comments closed

Related News

June 16, 2024

Bayer’s biotech head Jens Vogel says good-bye after 4 years

Life sciences

While Vogel didn’t cite any broader organizational changes as the reason behind his resignation, his departure comes amid a heavy-handed restructuring at the German pharma. Back in January, Bayer unveiled plans that have ultimately led to the elimination of more than 1,500 roles in the first three months of 2024.

June 16, 2024

Ventilator maker Vyaire Medical files for bankruptcy

Life sciences

The global ventilation and respiratory device manufacturer—originally spun out as a joint venture between BD and Apax Partners in 2016—said its decision followed “below-plan performance in the first half of the financial year, which frustrated efforts to refinance company debt,” and that Vyaire will remain open for business in the interim.

June 16, 2024

Pfizer, Flagship name first target for multibillion-dollar collaboration: obesity

Life sciences

Pfizer and Flagship Pioneering have settled on the first target for their billion-dollar, multiprogram collaboration, and it’s not exactly a surprise: The New York Big Pharma giant will work with the venture creation firm’s ProFound Therapeutics to develop new obesity drugs.

How can we help you?

We're easy to reach